Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company is expected to achieve a net profit attributable to shareholders of 63 million yuan in 2025, representing a year-on-year increase of 46%. The growth is supported by the expansion into overseas markets and new application fields [5][8] - The company's revenue for 2025 is projected to be 406 million yuan, reflecting a year-on-year growth of 19.62%. This growth is driven by the synergy of three major business segments: vaccine culture media, food nutrition products, and raw materials [8] - The company is actively establishing overseas subsidiaries to enhance market presence and streamline trade processes, which is expected to contribute to long-term growth [8] Financial Summary - Revenue Forecast: - 2023: 389 million yuan - 2024: 339 million yuan (decrease of 12.87%) - 2025E: 406 million yuan (increase of 19.62%) - 2026E: 482 million yuan (increase of 18.98%) - 2027E: 573 million yuan (increase of 18.73%) [7] - Net Profit Forecast: - 2023: 53 million yuan - 2024: 43 million yuan (decrease of 19.76%) - 2025E: 63 million yuan (increase of 46.38%) - 2026E: 79 million yuan (increase of 25.87%) - 2027E: 97 million yuan (increase of 23.12%) [7] - Earnings Per Share (EPS): - 2023: 0.69 yuan - 2024: 0.55 yuan - 2025E: 0.81 yuan - 2026E: 1.02 yuan - 2027E: 1.25 yuan [7] - Price-to-Earnings Ratio (P/E): - 2025E: 29.29 - 2026E: 23.27 - 2027E: 18.90 [7]
无锡晶海（920547）：2025年归母净利润预计同比+46%，开拓海外市场+新应用领域支撑未来业绩增长：无锡晶海（920547.BJ）